Sign In
Last checked at 
19 Jun 2024 11:33
19 June 2024
ValiRx PLC
("ValiRx" or the "Company")
Directorate Change
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that Kevin Cox has resigned as Chairman and Director of the Company with immediate effect.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.
*** ENDS ***
For more information, please contact:
ValiRx plc
Dr Suzanne Dilly, CEO
| Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
| +44 (0) 115 787 0206 www.vformation.biz
lucy@vformation.biz sue@vformation.biz |
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/ Ludovico Lazzaretti
| Tel: +44 (0) 20 7213 0880 |
Shard Capital Partners LLP (Sole Broker)
Damon Heath
| Tel: +44 (0) 20 7186 9000 |
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Follow the stocks
